Financial Performance - Total revenue for Q4 2023 was $135.5 million, an increase of 2.2% from Q4 2022[3] - Net income for Q4 2023 was $7.1 million, a decrease of 40.1% compared to Q4 2022, with diluted earnings per share of $0.03[4] - Normalized Funds From Operations (FFO) for Q4 2023 was $64.1 million, or $0.26 per share on a fully diluted basis[6] - Total revenues for Q4 2023 were $135.472 million, a 2.9% increase from $132.565 million in Q4 2022[23] - Net income for Q4 2023 was $7.122 million, down 40.1% from $11.881 million in Q4 2022[23] - Rental and related revenues for the year ended December 31, 2023, were $528.093 million, compared to $515.373 million in 2022, reflecting a 2.5% increase[23] - Basic earnings per share for Q4 2023 were $0.03, down from $0.05 in Q4 2022[29] - Total revenue for the year ended December 31, 2023, was $43.767 million, down from $110.036 million in 2022, representing a decline of 60.2%[30] Investments and Expenses - The company completed $47.4 million in investments during Q4 2023, including funding of previous loan commitments[4] - The company recorded merger and transaction-related expenses of $6.9 million in 2023 related to the proposed merger with Healthpeak[23] - General and administrative expenses decreased to $7.623 million in Q4 2023 from $9.809 million in Q4 2022, a reduction of 22.3%[30] - Merger and transaction-related expenses amounted to $6.934 million in 2023, primarily due to the proposed merger with Healthpeak[30] Portfolio and Leasing - The consolidated portfolio was approximately 94.3% leased as of December 31, 2023[3] - The weighted average leasing spread for the year ended 2023 was 4.2% with a 74% retention rate[4] - Outpatient Medical Same-Store Cash Net Operating Income growth was 1.0% year-over-year for Q4 2023[8] - Outpatient Medical Same-Store Cash NOI for Q4 2023 was $84.555 million, up from $83.734 million in Q4 2022, an increase of 1.0%[30] Cash and Assets - Total assets as of December 31, 2023, were $5.156 billion, compared to $5.097 billion as of December 31, 2022, representing a 1.2% increase[27] - Total liabilities increased to $2.266 billion in 2023 from $2.100 billion in 2022, a rise of 7.9%[27] - Cash and cash equivalents increased significantly to $156.779 million in 2023 from $7.730 million in 2022[27] Earnings and Dividends - A quarterly dividend of $0.23 per share was declared for Q4 2023, paid on January 18, 2024[13] - The company declared dividends of $0.23 per common share for both Q4 2023 and Q4 2022[29] Other Financial Metrics - EBITDAre for Q4 2023 was $77.164 million, down from $82.958 million in Q4 2022, reflecting a decrease of 7.0%[32] - Adjusted EBITDAre increased to $89.984 million in Q4 2023 from $87.914 million in Q4 2022, an increase of 2.4%[32] - Cash NOI for the year was $371.506 million, compared to $367.248 million in 2022, showing a growth of 1.0%[30] - Interest expense rose to $21.514 million in Q4 2023, compared to $19.878 million in Q4 2022, an increase of 8.2%[32] - The company recorded a non-cash share compensation expense of $3.386 million in Q4 2023, slightly up from $3.272 million in Q4 2022[32] Mergers and Acquisitions - The company announced an all-stock merger with Healthpeak Properties, expected to close on or about March 1, 2024[2]

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: PEAK) (“Healthpeak”) today announced, in connection with its previously announced agreement to merge with Physicians Realty Trust (NYSE: DOC) (“Physicians Realty Trust” or “DOC”), that it and Healthpeak OP, LLC (“Healthpeak OP”), a direct subsidiary of Healthpeak, have commenced a consent solicitation to certain proposed amendments to each of the supplemental indentures to the Senior Indenture (each an “Indenture”) governing the following outstandi ...

Healthpeak Properties, Inc. (PEAK) Q4 2023 Earnings Conference Call February 9, 2024 10:00 AM ET Andrew Johns - Senior Vice President, Investor Relations Scott Brinker - President and Chief Executive Officer Pete Scott - Chief Financial Officer John Thomas - Chief Executive Officer, Physicians Realty Trust Scott Bohn - Chief Development Officer and Head, Lab Tom Klaritch - Chief Operating Officer Shawn John - Executive Vice President and Chief Accounting Officer Nick Yulico - Scotiabank Juan Sanabria - BMO ...

NEW YORK, Jan. 26, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.  Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process:  Physicians Realty Trust (NYSE: DOC) click ...

Healthpeak Properties, Inc. (PEAK) Q3 2023 Earnings Conference Call October 30, 2023 10:00 AM ET Andrew Johns - Senior Vice President, Investor Relations Scott Brinker - President and Chief Executive Officer Peter Scott - Chief Financial Officer John Thomas - President and Chief Executive Officer of Physicians Realty Trust Scott Bohn - Chief Development Officer and Co-Head of Life Science Company Participants Conference Call Participants Michael Griffin - Citigroup Austin Wurschmidt - KeyBanc Capital Market ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36007 PHYSICIANS REALTY TRUST (Exact Name of Registrant as Specified in its Charter) Maryland 46-2519850 (State of Organization) (IRS ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Securities registered pursuant to Section 12(b) of the Act: | | | Name of each exchange on which | | --- | --- | --- | | Title of each class | Trading Symbol | registe ...

We expect this to be a growth strategy for us as the first of many similar cardiology focused outpatient facilities, we will purchase development finance in the future. In each case, these projects will soon be helping leading healthcare providers deliver care in their communities. Jeff will now share comments on our financial results of second quarter 2023 and Mark will discuss our operating results. Jeff? We closed on a five-year $400 million term loan in May, and concurrently entered into a five-year swa ...

PHYSICIANS REALTY TRUS Invest in better. 1 DOC Portfolio 290 97% 89% 95% 67% Assets Owned of NOI from MOBs On-Campus / Affiliated (% ABR) Portfolio Leased Rate IG Tenancy(1) (% GLA) PHYSICIANS REALTY TRUST Purchase Price Portfolio Square Footage DOC 1st Year Cash Cap Rate Management Team • Former lead Health Care and Lab Space Equity Research Analyst at Green Street Advisors • Former real estate investment banker at Lehman Brothers and Bank of America • Former Director of Financial Reporting with Assisted L ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36007 PHYSICIANS REALTY TRUST (Exact Name of Registrant as Specified in its Charter) 309 N. Water Street, Suite 500 Milwaukee, Wisconsin 5 ...